POET Trial Reveals Cost Benefits of Oral Antibiotic Treatment in Endocarditis
A recent analysis from the POET trial indicates significant cost savings associated with oral step-down antibiotic treatment for infective endocarditis.
Oral step-down treatment shows lower all-cause mortality and fewer hospital stays.
Cost savings per patient range from €10,946 to €16,888 depending on the causative microorganism.
The findings support the adoption of oral antibiotics in clinical practice for stable endocarditis patients.
The POET trial has challenged traditional treatment protocols for infective endocarditis, demonstrating that oral step-down antibiotic therapy is as effective as conventional intravenous treatment in clinically stable patients with left-sided endocarditis. After a median follow-up period of 5.4 years, researchers found that patients receiving oral treatment experienced lower rates of all-cause mortality, unplanned cardiac surgeries, and other complications compared to those on intravenous therapy.
Historically, infective endocarditis has been treated with intravenous antibiotics, particularly for cases caused by common pathogens such as Streptococcus spp., Enterococcus faecalis, and Staphylococcus aureus. These microorganisms account for over 70% of endocarditis cases, necessitating varied treatment regimens that influence hospitalization duration and overall costs. The POET trial's findings suggest that oral step-down therapy could be a viable alternative, particularly for patients who have stabilized.
In a detailed cost analysis involving 380 patients, the study revealed that those on oral step-down treatment saved an average of €10,946 for Streptococcus spp., €16,888 for E. faecalis, and €11,781 for S. aureus. The analysis, conducted from a Danish hospital perspective, focused on costs incurred from randomization to the completion of antibiotic treatment, including hospital stays and outpatient visits. The significant cost savings were primarily attributed to reduced hospital stays, with patients on oral treatment discharged earlier than those receiving intravenous therapy.
The implications of these findings extend beyond individual patient care, suggesting a potential shift in treatment protocols across European healthcare systems. The substantial savings observed, especially in cases of E. faecalis endocarditis, highlight the need for healthcare providers to consider oral step-down therapy as a standard practice. This approach not only alleviates hospital resource strain but also enhances patient care by allowing for quicker discharges and reduced healthcare costs.
Looking ahead, the research underscores the importance of identifying suitable candidates for oral step-down treatment in clinical settings. Future studies may further explore the long-term economic impacts and clinical outcomes associated with this treatment strategy, reinforcing its role in modern endocarditis management.
